Vir Biotechnology, Inc. Research and Development Expense
Vir Biotechnology, Inc. (VIR) reported Research and Development Expense of $135.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Vir Biotechnology, Inc. research and development expense for the quarter ending 2026-06-30 was $135.28M, a 38.74% increase year-over-year.
- Vir Biotechnology, Inc. research and development expense for the quarter ending 2026-03-31 was $108.92M, a 8.20% decline year-over-year.
- Vir Biotechnology, Inc. research and development expense for the quarter ending 2025-12-31 was $88.35M, a 16.72% decline year-over-year.
- Vir Biotechnology, Inc. research and development expense for the quarter ending 2025-09-30 was $151.46M, a 22.40% decline year-over-year.
- Vir Biotechnology, Inc. research and development expense for fiscal 2025 was $455.97M, a 9.98% decline from fiscal 2024.
- Vir Biotechnology, Inc. research and development expense for fiscal 2024 was $506.50M, a 12.63% decline from fiscal 2023.
- Vir Biotechnology, Inc. research and development expense for fiscal 2023 was $579.72M, a 22.14% increase from fiscal 2022.
- Vir Biotechnology, Inc. research and development expense for fiscal 2022 was $474.65M, a 5.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $135.28M 10-Q · filed 2026-08-05 | $244.21M 10-Q · filed 2026-08-05 | $332.55M derived: sum of 3 quarters · filed 2026-08-05 | $484.02M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $108.92M 10-Q · filed 2026-05-07 | $197.27M derived: sum of 2 quarters · filed 2026-05-07 | $348.73M derived: sum of 3 quarters · filed 2026-05-07 | $446.24M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $88.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $239.81M derived: sum of 2 quarters · filed 2026-02-23 | $337.32M derived: sum of 3 quarters · filed 2026-08-05 | $455.97M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $151.46M 10-Q · filed 2025-11-05 | $248.97M derived: sum of 2 quarters · filed 2026-08-05 | $367.62M 10-Q · filed 2025-11-05 | $473.70M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $97.51M 10-Q · filed 2026-08-05 | $216.15M 10-Q · filed 2026-08-05 | $322.24M derived: sum of 3 quarters · filed 2026-08-05 | $517.41M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $118.64M 10-Q · filed 2026-05-07 | $224.73M derived: sum of 2 quarters · filed 2026-05-07 | $419.91M derived: sum of 3 quarters · filed 2026-05-07 | $525.02M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $106.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $301.26M derived: sum of 2 quarters · filed 2026-02-23 | $406.37M derived: sum of 3 quarters · filed 2026-02-23 | $506.50M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $195.18M 10-Q · filed 2025-11-05 | $300.29M derived: sum of 2 quarters · filed 2025-11-05 | $400.42M 10-Q · filed 2025-11-05 | $509.38M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $105.11M 10-Q · filed 2025-08-06 | $205.24M 10-Q · filed 2025-08-06 | $314.20M derived: sum of 3 quarters · filed 2026-02-23 | $459.23M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $100.13M 10-Q · filed 2025-05-08 | $209.09M derived: sum of 2 quarters · filed 2026-02-23 | $354.12M derived: sum of 3 quarters · filed 2026-02-23 | $522.20M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $108.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $253.99M derived: sum of 2 quarters · filed 2026-02-23 | $422.08M derived: sum of 3 quarters · filed 2026-02-23 | $579.72M 10-K · filed 2026-02-23 | $589.67M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $145.03M 10-Q · filed 2024-11-04 | $148.25M 10-Q · filed 2023-11-03 | $313.11M derived: sum of 2 quarters · filed 2024-11-04 | $470.75M 10-Q · filed 2024-11-04 | $477.76M 10-Q · filed 2023-11-03 | $625.93M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $168.08M 10-Q · filed 2024-08-01 | $171.86M 10-Q · filed 2023-08-04 | $325.73M 10-Q · filed 2024-08-01 | $329.50M 10-Q · filed 2023-08-04 | $480.90M derived: sum of 3 quarters · filed 2025-02-27 | $595.07M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $157.64M 10-Q · filed 2024-05-03 | $312.82M derived: sum of 2 quarters · filed 2025-02-27 | $426.98M derived: sum of 3 quarters · filed 2025-02-27 | $542.06M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $155.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $269.34M derived: sum of 2 quarters · filed 2025-02-27 | $384.42M derived: sum of 3 quarters · filed 2025-02-27 | $474.65M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $114.17M 10-Q · filed 2023-11-03 | $229.25M derived: sum of 2 quarters · filed 2023-11-03 | $319.48M 10-Q · filed 2023-11-03 | $447.82M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $115.08M 10-Q · filed 2023-08-04 | $205.31M 10-Q · filed 2023-08-04 | $333.65M derived: sum of 3 quarters · filed 2024-02-26 | $432.32M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $90.23M 10-Q · filed 2023-05-08 | $218.57M derived: sum of 2 quarters · filed 2024-02-26 | $317.24M derived: sum of 3 quarters · filed 2024-02-26 | $403.36M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $128.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $227.01M derived: sum of 2 quarters · filed 2024-02-26 | $313.14M derived: sum of 3 quarters · filed 2024-02-26 | $448.01M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $98.67M 10-Q · filed 2022-11-03 | $184.79M derived: sum of 2 quarters · filed 2022-11-03 | $319.67M 10-Q · filed 2022-11-03 | $406.76M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $86.13M 10-Q · filed 2022-08-09 | $221.00M 10-Q · filed 2022-08-09 | $308.09M derived: sum of 3 quarters · filed 2023-02-28 | $378.77M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $134.87M 10-Q · filed 2022-05-05 | $221.97M derived: sum of 2 quarters · filed 2023-02-28 | $292.65M derived: sum of 3 quarters · filed 2023-02-28 | $372.30M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $87.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $157.78M derived: sum of 2 quarters · filed 2023-02-28 | $237.43M derived: sum of 3 quarters · filed 2023-02-28 | $302.41M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $70.68M 10-Q · filed 2021-11-04 | $150.34M derived: sum of 2 quarters · filed 2021-11-04 | $215.32M 10-Q · filed 2021-11-04 | $268.25M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $79.65M 10-Q · filed 2021-08-05 | $144.63M 10-Q · filed 2021-08-05 | $197.56M derived: sum of 3 quarters · filed 2022-02-28 | $237.43M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $64.98M 10-Q · filed 2021-05-06 | $117.91M derived: sum of 2 quarters · filed 2022-02-28 | $157.77M derived: sum of 3 quarters · filed 2022-02-28 | $187.58M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $52.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $92.79M derived: sum of 2 quarters · filed 2022-02-28 | $122.60M derived: sum of 3 quarters · filed 2022-02-28 | $148.47M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $39.86M 10-Q · filed 2020-11-10 | $69.67M derived: sum of 2 quarters · filed 2020-11-10 | $95.54M 10-Q · filed 2020-11-10 | $117.51M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $29.80M 10-Q · filed 2020-08-11 | $55.68M 10-Q · filed 2020-08-11 | $77.65M derived: sum of 3 quarters · filed 2021-02-25 | $107.49M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $25.87M 10-Q · filed 2020-05-12 | $47.84M derived: sum of 2 quarters · filed 2021-02-25 | $77.68M derived: sum of 3 quarters · filed 2021-02-25 | |||||
| 2018-12-31 | $21.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $51.81M derived: sum of 2 quarters · filed 2021-02-25 | $100.23M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $29.84M 10-Q · filed 2019-11-19 | $78.26M 10-Q · filed 2019-11-19 | ||||||
| 2017-12-31 | $62.51M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |